05 July 2022: Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
Xenia Bacinschi 1E , Gabriel Cristian Popescu 2C , Anca Zgura 1C* , Laurentia Gales 1F , Anghel Rodica 1A , Adriana Mercan 3D , Dragos Serban 4D , Bogdan Haineala 5B , Letitia Toma 3C , Laura Iliescu 3FDOI: 10.12659/MSM.936706
Med Sci Monit 2022; 28:e936706
Table 3 Biologic abnormalities during direct-acting antiviral agent therapy in patients with and without ribavirin.
| Total group (N=587 patients) | With ribavirin (n=245 patients) | Without ribavirin (n=343 patients) | Chi-square | |
|---|---|---|---|---|
| Anemia | 293 patients (49.91%) | 245 patients (100.0%) | 38 patients (11.07%) | −0.82 |
| Liver cytolysis | 46 patients (7.83%) | 28 patients (11.42%) | 18 patients (5.24%) | −0.41 |
| Cholestasis | 37 patients (6.30%) | 15 patients (6.12%) | 12 patients (3.49%) | −0.23 |